ClinicalTrials.gg
RecruitingNCT06046417FCLUpdated Apr 18, 2024

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

A Phase 2/3 interventional study of Pramlintide and Lyumjev in type1diabetes and Diabetes Mellitus, Type 1, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing pramlintide in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. pramlintide · Diabetes Mellitus, Type 1.

Planned enrollment
9th of 22
30 · median 27
Started
2023
the only one that year
Phase 2/3
Only one
of the 22
Registered
22nd of 22
by date
Lead sponsor
2 of 22
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 22 studies testing pramlintide in Diabetes Mellitus, Type 1, this one is the 9th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2/3, and was the 22nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 22 studies testing pramlintide in Diabetes Mellitus, Type 1 is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About pramlintide

pramlintide: first FDA approval 2005 (SYMLIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing pramlintide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The aim of this clinical trial is to investigate whether a fully automated Lyumjev-and-pramlintide delivery system improves glycemic outcomes in adults with type 1 diabetes. The main question we aim to answer is whether a Lyumjev-pramlintide fully closed loop system improves time in range compared to a hybrid closed loop system with carbohydrate counting. We also aim to find the optimal insulin to pramlintide ratio for glycemic control in the fully automated system.

In this cross-over study, patients will undergo the following three interventions in a random order:

(i) fully automated Lyumjev insulin-and-pramlintide (8 μg/u) (ii) fully automated Lyumjev insulin-and-pramlintide (10 μg/u) (iii) rapid automated Lyumjev insulin-and-placebo with carbohydrate-matched boluses

For all interventions, participants will be required to wear two Ypsomed pumps programmed by our developed EuGlide system.

Read the detailed description

The aim of this study is to conduct an outpatient, randomized, crossover clinical trial to compare the glycemic outcomes of a fully automated Lyumjev-pramlintide delivery system to a hybrid automated Lyumjev-placebo delivery system with carbohydrate counting in 26 adults with type 1 diabetes.

Design-

All participants will undergo three interventions in a random order:

(i) Fully automated Lyumjev insulin-pramlintide delivery system. Ratio of 1 unit of inulin for 8μg of pramlintide.

(ii) Fully automated Lyumjev insulin-pramlintide delivery system. Ratio of 1 unit of insulin for 10μg of pramlintide.

(iii) Hybrid automated Lyumjev insulin-placebo delivery system with carbohydrate-matched boluses.

Study drugs-

Lyumjev is a Health Canada insulin for treatment of type 1 diabetes. Participants who do not currently use Lyumjev will be switched to it for the duration of the study.

Pramlintide is an FDA-approved drug used in the treatment of type 1 diabetes. It contributes to regulating glucose levels by delaying gastric emptying, suppressing nutrient-stimulated glucagon secretion and increasing satiety. It is not approved for commercial use by Health Canada, but has been approved for the purpose of the study.

Study Devices-

For the duration of the study, participants will use a Dexcom G6 Continuous Glucose Monitor (GCM), two YpsoPumps (for insulin and pramlintide) as well as a study smartphone with the Euglide application installed. The automated insulin delivery (AID) system will integrate these sets of devices to automate insulin (and pramlintide) delivery in response to an individual's glucose levels.

Treatment Period-

Each intervention will last three weeks and be preceded by a 5-day at-home run-in period. After both the second and third interventions, there will be a 14-45 day washout period. Participants will be followed-up with remotely on days 2 (+/-1) and 5 of each run-in and on days 2(+/-1), 3(+/-1) and 7(+/-2) of each intervention. Remote contact can be performed via phone, email, text message or another reasonable communication channel. After each intervention, participants will be interviewed and asked to complete questionnaires assessing diabetes control and quality of life. Participants will need approximately 15-30 weeks to complete the study.

The study will enroll up to 4 pilot participants, as well as 26 main study participants who meet the eligibility criteria.

03

Conditions studied

  • type1diabetes
  • Diabetes Mellitus, Type 1

Keywords

  • Pramlintide
  • fully automated delivery system
  • artificial pancreas
  • Insulin
  • Lyumjev
  • fully closed loop
  • adjunctive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals ≥ 18 years of age.
  • A clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes relies on the investigator's judgment; C peptide level and antibody determinations are unnecessary.
  • Using insulin pump therapy for at least three months.
  • Individuals of using an effective birth-control method. An individual of childbearing potential must agree to use a highly effective method of .

Exclusion criteria

Exclusion Criteria:

  • Current or recent use of antihyperglycemic agents other than insulin (≤ 2-week use of sodium-glucose cotransporter-2 inhibitor (SGLT2I), Metformin, etc.; ≤ 1-month for glucagon-like peptide-1 receptor agonists (GLP1-RA)).
  • Current use of medication (except low, stable doses and inhaled steroids).
  • Individuals with confirmed gastroparesis.
  • Use of medication that alters gastrointestinal motility (ex: domperidone).
  • Use of hydroxyurea.
  • Planned or ongoing pregnancy.
  • Breastfeeding individuals.
  • Severe hypoglycemia requiring hospitalization in the past month. Severe hypoglycemia is defined as requiring the assistance of another person, due to altered consciousness, to administer carbohydrates, glucagon, or other resuscitative actions.
  • Diabetic ketoacidosis episode in the past month.
  • nephropathy, neuropathy, or retinopathy as judged by the investigator.
  • Recent (\< 6 months) acute macrovascular event, e.g., acute coronary syndrome.
  • Other serious medical illnesses which are likely to interfere with study participation or the ability to complete the trial by the investigator's judgment.
  • Known to the study drugs or their .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Fully automated Lyumjev-and-pramlintide delivery system (8 μg/u)

    Lyumjev and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 8 μg of pramlintide.

    Drug: Pramlintide · Drug: Lyumjev · Device: Automated Insulin Delivery (AID) system

  • Experimental
    Fully automated Lyumjev-and-pramlintide delivery system (10 μg/u)

    Lyumjev and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 10 μg of pramlintide.

    Drug: Pramlintide · Drug: Lyumjev · Device: Automated Insulin Delivery (AID) system

  • Active comparator
    Hybrid automated Lyumjev-and-placebo delivery system with carbohydrate-matched boluses

    Lyumjev and saline placebo hybrid automated delivery system with meal announcement. Participants must input the carbohydrate content of their meals to inform the insulin bolus doses based on their pre-programmed insulin-to-carbohydrate ratios.

    Drug: Lyumjev

Interventions

  • Pramlintide delivered in a basal-bolus manner.

  • DrugInsulin LisproStudies of Insulin LisproInsulin Lispro pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lyumjev delivered in a basal-bolus manner.

  • DeviceAutomated Insulin Delivery (AID) system

    The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.

06

What researchers measure

Primary outcomes

  1. Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).

    Time frame: 18 days

Secondary outcomes

  1. Percentage of time of glucose levels spent between 3.9-7.8 mmol/L.

    Time frame: 18 days

  2. Percentage of time of glucose levels spent between 3.0-3.9 mmol/L.

    Time frame: 18 days

  3. Percentage of time of glucose levels spent between 10.0-13.9 mmol/L.

    Time frame: 18 days

  4. Mean glucose levels.

    Time frame: 18 days

  5. Standard deviation of glucose levels.

    Time frame: 18 days

  6. Coefficient of variance of glucose levels.

    Time frame: 18 days

  7. Total pramlintide delivery (overall, basal, and bolus).

    Time frame: 18 days

  8. Total insulin delivery (overall, basal, and bolus).

    Time frame: 18 days

  9. Mean score on the Type 1 Diabetes Distress Scale (T1DDS) excluding the physician subscale.

    A scale from 1-6 indicating overall diabetes distress. Higher scores indicate higher levels of diabetes distress. Any total subscale score of \>2.0 is considered clinically significant.

    Time frame: 18 days

  10. Mean score on the Hypoglycemia Fear Survey - II (Worry Subscale) (HSF2).

    A scale from 1-5 with higher scores indicating a greater fear of hypoglycemia.

    Time frame: 18 days

  11. Mean score on the INSPIRE questionnaire for adults (INSPIRE).

    A scale from 1-5 with higher scores reflecting more favorable opinions about using Automated Insulin Delivery (AID).

    Time frame: 18 days

  12. Mean score on selected items from The Diabetes Bowel Symptoms Questionnaire (DBSQ).

    A 1-5 scale with higher values reflecting a greater quantity and severity of diabetes bowel symptoms.

    Time frame: 18 days

  13. Mean score on a Treatment Satisfaction Questionnaire (TSQ) taken from Marrero et al.

    A 1-6 scale with higher values indicating more satisfaction with treatment.

    Time frame: 18 days

  14. Thematic interview analysis

    Semi-structured interviews will be carried out after every intervention. We will analyze their qualitative content.

    Time frame: 18 days

Other outcomes

  1. Safety Endpoints

    Number of adverse events, including gastrointestinal symptoms.

    Time frame: 18 days

07

Study locations

1 of 1 sites recruiting
  • Research Institute of the McGill University Health Center
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Joelle Doumat, BSc. · Contactjoelle.doumat@mail.mcgill.ca · 832-798-3648
    • Michael Tsoukas, M.D · Principal investigator
    • Ahmad Haidar, PhD. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The raw data (that is, insulin delivery, glucose levels and individual participant data) and informed consent form will be shared by the corresponding author, for academic purposes, subject to a material transfer agreement and approval of the McGill University Health Center's Research Ethics Board. All data shared will be de-identified. Raw data will be shared for non-commercial use upon reasonable request and a material transfer agreement.

Supporting information: Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Apr 2025, 17 months after the start.

Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Nov 30, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Jun 2025
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046417
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
Michael Tsoukas (Assistant Professor, Endocrinology & Metabolism, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Sep 21, 2023
Start date
Nov 30, 2023
Primary completion
Apr 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Apr 18, 2024

Study contacts

Joelle Doumat, BSc.
Contact
joelle.doumat@mail.mcgill.ca
832-798-3648
Ahmad Haidar, PhD.
Contact
Michael Tsoukas, M.D.
principal investigator · Research Institute of the McGill University Health Center
Ahmad Haidar, Ph.D.
study chair · Research Institute of the McGill University Health Center
Laurent Legault, M.D.
study chair · Montreal's Children's Hospital Division of Endocrinology
Michael Vallis, Ph.D.
study chair · Dalhousie University Psychologist
Natasha Garfield, M.D.
study chair · Royal Victoria Hospital Division of Endocrinology
Melissa-Rosina Pasqua, M.D.
study chair · Research Institute of the McGill University Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramlintide

Start the discussion